Protox appoints chief financial officer
This article was originally published in Scrip
Protox Therapeutics, a company specialising in the development of receptor targeted fusion proteins, has appointed John Parkinson chief financial officer. Mr Parkinson previously held the role of vice-president, finance at Aspreva Pharmaceuticals. He takes over his new role from David Swetlow, vice president of finance and operations, who has resigned.